Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVX-CoV2705 Omicron JN.1 Vaccine in Adults 50 to < 65 Years
NCT07086222Phase 4Terminated
- Sponsor
- Novavax
- Start
- Nov 2025
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing NVX-CoV2705 with Placebo (2 arms). Primary endpoint: First episode of PCR-positive symptomatic COVID-19 at 180 days. Started Nov 2025; status: terminated.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07086222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07086222.